Publication: Dengue-4 vaccine: Neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys
Issued Date
1988-01-01
Resource Type
ISSN
18783503
00359203
00359203
Other identifier(s)
2-s2.0-0023692202
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.82, No.5 (1988), 746-749
Suggested Citation
Subhkij Angsubhakorn, Sutee Yoksan, Natth Bhamarapravati, James B. Moe, Nyven J. Marchette, Apichat Pradermwong, Somphong Sahaphong Dengue-4 vaccine: Neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys. Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.82, No.5 (1988), 746-749. doi:10.1016/0035-9203(88)90224-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/15581
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Dengue-4 vaccine: Neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys
Other Contributor(s)
Abstract
A dengue 4 (DEN-4, strain 1036-PDK 48) vaccine attenuated by passage in primary dog kidney cells was tested using rhesus (Macaca mulatto) and cynomolgus (M. fascicularis) monkeys to determine its safety, potency, and immunogenicity. 14 rhesus monkeys were divided into 3 groups: group 1, 2 animals given control culture fluid; group 2, 2 animals given DEN-4 parental virus; group 3, 10 animals given DEN-4 vaccine virus. 10 cynomolgus were similarly grouped, but group 3 contained 6 monkeys. No significant neurovirulence was observed with parental or with DEN-4 virus passaged in primary dog kidney (PDK) cells. Both cynomolgus monkeys inoculated with DEN-4 vaccine virus developed minimal (V-l) and mild (V-2) neurovirulence-type lesions in the central nervous system, which were nondestructive in both species. All parental and vaccine viruses produced moderate to high neutralizing antibody titres. Only parental virus produced viraemia, in 2 cynomolgus monkeys. Because of its safety and avirulence in monkeys, PDK 48 is recommended for human trial. © Royal Society of Tropical Medicine and Hygiene.